1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

 
• By Sukaina Virji

Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.

Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.

“These are the first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis,”...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 
• By Sushmita Panda

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Avalyn Raises $100m Series D To Advance Inhaled Pulmonary Fibrosis Candidates

 
• By Joseph Haas

Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

More from Therapy Areas

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.